CoChat

Sequence-based drug design as a concept in computational drug design

Open access
Chen, Lifan, Fan, Zisheng, Chang, Jie, Yang, Ruirui, Hou, Hui, Guo, Hao, Zhang, Yinghui, Yang, Tianbiao, Zhou, Chenmao, Sui, Qibang, Chen, Zhengyang, Zheng, Chen, Hao, Xinyue, Zhang, Keke, Cui, Rongrong, Zhang, Zehong, Ma, Hudson, Ding, Yiluan, Zhang, Naixia, Lu, Xiaojie, Luo, Xiaomin, Jiang, Hualiang, Zhang, Sulin, Zheng, Mingyue · 2023 · Nature Communications
Cited by 124

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Drug development based on target proteins has been a successful approach in recent decades. However, the conventional structure-based drug design (SBDD) pipeline is a complex, human-engineered process with multiple independently optimized steps. Here, we propose a sequence-to-drug concept for computational drug design based on protein sequence information by end-to-end differentiable learning. We validate this concept in three stages. First, we design TransformerCPI2.0 as a core tool for the concept, which demonstrates generalization ability across proteins and compounds. Second, we interpret the binding knowledge that TransformerCPI2.0 learned. Finally, we use TransformerCPI2.0 to discover new hits for challenging drug targets, and identify new target for an existing drug based on an inverse application of the concept. Overall, this proof-of-concept study shows that the sequence-to-drug concept adds a perspective on drug design. It can serve as an alternative method to SBDD, particularly for proteins that do not yet have high-quality 3D structures available.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-39856-w

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 54

  1. Gorgulla, C. et al. An open-source drug discovery platform enables ultra-large virtual screens. Nature 580, 663–668 (2020). · DOI · Paper page
  2. Zheng, M. et al. Computational chemical biology and drug design: facilitating protein structure, function, and modulation studies. Med. Res. Rev. 38, 914–950 (2018). · DOI
  3. Zheng, M. et al. Computational methods for drug design and discovery: focus on China. Trends Pharmacol. Sci. 34, 549–559 (2013). · DOI
  4. Tong, A. B. et al. Could AlphaFold revolutionize chemical therapeutics? Nat. Struct. Mol. Biol. 28, 771–772 (2021). · DOI · Paper page
  5. Mullard, A. What does AlphaFold mean for drug discovery. Nat. Rev. Drug Discov. 20, 725–727 (2021). · DOI · Paper page
  6. Kitchen, D. B., Decornez, H., Furr, J. R. & Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. 3, 935–949 (2004). · DOI · Paper page
  7. Stank, A., Kokh, D. B., Fuller, J. C. & Wade, R. C. Protein binding pocket dynamics. Acc. Chem. Res. 49, 809–815 (2016). · DOI · Paper page
  8. Zhu, T. et al. Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. J. Med. Chem. 56, 6560–6572 (2013). · DOI · Paper page
  9. Nguyen, T. et al. GraphDTA: predicting drug–target binding affinity with graph neural networks. Bioinformatics 37, 1140–1147 (2020). · DOI · Paper page
  10. Li, S. et al. MONN: a multi-objective neural network for predicting compound-protein interactions and affinities. Cell Syst. 10, 308–322.e311 (2020). · DOI · Paper page
  11. Ozturk, H., Ozgur, A. & Ozkirimli, E. DeepDTA: deep drug-target binding affinity prediction. Bioinformatics 34, i821–i829 (2018). · DOI · Paper page
  12. Karimi, M., Wu, D., Wang, Z. & Shen, Y. DeepAffinity: interpretable deep learning of compound–protein affinity through unified recurrent and convolutional neural networks. Bioinformatics 35, 3329–3338 (2019). · DOI · Paper page
  13. Zhao, Q., Zhao, H., Zheng, K. & Wang, J. HyperAttentionDTI: improving drug–protein interaction prediction by sequence-based deep learning with attention mechanism. Bioinformatics 38, 655–662 (2021). · DOI · Paper page
  14. Yang, Z., Zhong, W., Zhao, L. & Chen, C. Y.-C. ML-DTI: mutual learning mechanism for interpretable drug–target interaction prediction. J. Phys. Chem. Lett. 12, 4247–4261 (2021). · DOI
  15. Kim, Q., Ko, J.-H., Kim, S., Park, N. & Jhe, W. Bayesian neural network with pretrained protein embedding enhances prediction accuracy of drug-protein interaction. Bioinformatics 37, 3428–3435 (2021). · DOI
  16. Cai, T. et al. MSA-regularized protein sequence transformer toward predicting genome-wide chemical-protein interactions: application to GPCRome deorphanization. J. Chem. Inf. Model. 61, 1570–1582 (2021). · DOI
  17. Huang, K., Xiao, C., Glass, L. M. & Sun, J. MolTrans: molecular interaction transformer for drug–target interaction prediction. Bioinformatics 37, 830–836 (2021). · DOI · Paper page
  18. Bauer, M. R., Ibrahim, T. M., Vogel, S. M. & Boeckler, F. M. Evaluation and optimization of virtual screening workflows with DEKOIS 2.0 – a public library of challenging docking benchmark sets. J. Chem. Inf. Model. 53, 1447–1462 (2013). · DOI · Paper page
  19. Bender, A. & Glen, R. C. A discussion of measures of enrichment in virtual screening: comparing the information content of descriptors with increasing levels of sophistication. J. Chem. Inf. Model. 45, 1369–1375 (2005). · DOI · Paper page
  20. Cunningham Brian, C. & Wells James, A. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244, 1081–1085 (1989). · DOI · Paper page
  21. Cote, B. et al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg. Med. Chem. Lett. 24, 917–922 (2014). · DOI
  22. Wensing, A. M. et al. 2019 update of the drug resistance mutations in HIV-1. To.p Antivir. Med. 27, 111–121 (2019).
  23. Khan, N. H. et al. HIV drug resistance mutations in patients with HIV and HIV-TB coinfection after failure of first-line therapy: a prevalence study in a resource-limited setting. J. Int. Assoc. Provid. AIDS Care 18, 2325958219849061 (2019). · doi:10.1177/2325958219849061
  24. Lai, M.-T. et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 58, 1652–1663 (2014). · DOI
  25. Smith, S. J. et al. Rilpivirine and doravirine have complementary efficacies against NNRTI-resistant HIV-1 mutants. J. Acquir. Immune Defic. Syndr. 72, 485–491 (2016). · DOI
  26. Stumpfe, D., Hu, Y., Dimova, D. & Bajorath, J. R. Recent progress in understanding activity cliffs and their utility in medicinal chemistry: miniperspective. J. Med. Chem. 57, 18–28 (2014). · DOI · Paper page
  27. Bajorath, J. Duality of activity cliffs in drug discovery. Expert Opin. Drug Discov. 14, 517–520 (2019). · DOI
  28. Abula, A. et al. Substitution effect of the trifluoromethyl group on the bioactivity in medicinal chemistry: statistical analysis and energy calculations. J. Chem. Inf. Model. 60, 6242–6250 (2020). · DOI
  29. Xu, L. et al. BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. Nature 425, 316–321 (2003). · DOI · Paper page
  30. Guo, Z.-Q. et al. Small-molecule targeting of E3 ligase adaptor SPOP in kidney cancer. Cancer Cell 30, 474–484 (2016). · DOI
  31. Li, G. et al. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell 25, 455–468 (2014). · DOI · Paper page
  32. Chappell, J., Sun, Y., Singh, A. & Dalton, S. MYC/MAX control ERK signaling and pluripotency by regulation of dual-specificity phosphatases 2 and 7. Genes Dev. 27, 725–733 (2013). · DOI
  33. Ariza, A. et al. Study of protein haptenation by amoxicillin through the use of a biotinylated antibiotic. PLoS ONE 9, e90891 (2014). · DOI
  34. Mora-Ochomogo, M. & Lohans, C. T. β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates. RSC Med. Chem. 12, 1623–1639 (2021). · DOI · Paper page
  35. Zhang, X. & Jia, Y. Recent advances in β-lactam derivatives as potential anticancer agents. Curr. Top. Med. Chem. 20, 1468–1480 (2020). · doi:10.2174/1568026620666200309161444
  36. Kamath, A. & Ojima, I. Advances in the chemistry of β-lactam and its medicinal applications. Tetrahedron 68, 10640–10664 (2012). · DOI · Paper page
  37. Palm, K., Stenberg, P., Luthman, K. & Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14, 568–571 (1997). · DOI · Paper page
  38. Spugnini, E. & Fais, S. Proton pump inhibition and cancer therapeutics: a specific tumor targeting or it is a phenomenon secondary to a systemic buffering? Semin. Cancer Biol. 43, 111–118 (2017). · DOI
  39. Singh, S. R. et al. The lipolysis pathway sustains normal and transformed stem cells in adult Drosophila. Nature 538, 109–113 (2016). · DOI
  40. Wang, G. et al. Arf1-mediated lipid metabolism sustains cancer cells and its ablation induces anti-tumor immune responses in mice. Nat. Commun. 11, 220 (2020). · DOI
  41. D’Souza-Schorey, C. & Chavrier, P. ARF proteins: roles in membrane traffic and beyond. Nat. Rev. Mol. Cell Biol. 7, 347–358 (2006). · DOI · Paper page
  42. Olbe, L., Carlsson, E. & Lindberg, P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat. Rev. Drug Discov. 2, 132–139 (2003). · DOI · Paper page
  43. Bühlmann, S. & Reymond, J.-L. ChEMBL-likeness score and database GDBChEMBL. Front. Chem. 8, 46 (2020). · DOI
  44. Chevillard, F. & Kolb, P. SCUBIDOO: a large yet screenable and easily searchable database of computationally created chemical compounds optimized toward high likelihood of synthetic tractability. J. Chem. Inf. Model. 55, 1824–1835 (2015). · DOI · Paper page
  45. Massarotti, A., Brunco, A., Sorba, G. & Tron, G. C. ZINClick: a database of 16 million novel, patentable, and readily synthesizable 1,4-disubstituted triazoles. J. Chem. Inf. Model. 54, 396–406 (2014). · DOI
  46. Visini, R., Awale, M. & Reymond, J.-L. Fragment database FDB-17. J. Chem. Inf. Model. 57, 700–709 (2017). · DOI
  47. Yang, T. et al. DrugSpaceX: a large screenable and synthetically tractable database extending drug space. Nucleic Acids Res. 49, D1170–D1178 (2021). · DOI
  48. Grygorenko, O. O. et al. Generating multibillion chemical space of readily accessible screening compounds. iScience 23 (2020). · DOI · Paper page
  49. Bepler, T. & Berger, B. Learning protein sequence embeddings using information from structure. Preprint at https://arxiv.org/abs/1902.08661 (2019). · arXiv
  50. Kipf, T. N. & Welling, M. Semi-supervised classification with graph convolutional networks. Preprint at https://arxiv.org/abs/1609.02907 (2016). · arXiv
  51. Liu, L. et al. On the variance of the adaptive learning rate and beyond. Preprint at https://arxiv.org/abs/1908.03265 (2019). · arXiv
  52. Gaulton, A. et al. The ChEMBL database in 2017. Nucleic Acids Res. 45, D945–D954 (2017). · DOI · Paper page
  53. Papadatos, G., Gaulton, A., Hersey, A. & Overington, J. P. Activity, assay and target data curation and quality in the ChEMBL database. J. Comput. Aided Mol. Des. 29, 885–896 (2015). · DOI · Paper page
  54. Kramer, C., Kalliokoski, T., Gedeck, P. & Vulpetti, A. The experimental uncertainty of heterogeneous public Ki data. J. Med. Chem. 55, 5165–5173 (2012). · DOI · Paper page

Cited by

See all 124

Metadata

Authors
Chen, L., Fan, Z., Chang, J., Yang, R., Hou, H., Guo, H., Zhang, Y., Yang, T., Zhou, C., Sui, Q., Chen, Z., Zheng, C., Hao, X., Zhang, K., Cui, R., Zhang, Z., Ma, H., Ding, Y., Zhang, N., Lu, X., Luo, X., Jiang, H., Zhang, S., & Zheng, M.
Venue
Nature Communications
Published
2023-07-14
Volume
14
Issue
1
Pages
4217-4217
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4384296638
Cited by
124
References
22
FWCI
16.32
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sequence-based drug design as a concept in computational drug design. https://app.cochat.ai/papers/10.1038/s41467-023-39856-w
The paper
Chen, L., Fan, Z., Chang, J., Yang, R., Hou, H., Guo, H., Zhang, Y., Yang, T., Zhou, C., Sui, Q., Chen, Z., Zheng, C., Hao, X., Zhang, K., Cui, R., Zhang, Z., Ma, H., Ding, Y., Zhang, N., . . . Zheng, M. (2023). Sequence-based drug design as a concept in computational drug design. Nature Communications. https://doi.org/10.1038/s41467-023-39856-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.